Publications & Presentations
In the list below we have curated a select set of recent publications and presentations. A short title and description is followed by a statement of why this publication might be of interest, then a full citation and link to the work follows.
2025
Rethinking Value Attribution for Combination Therapies
Pricing combination products: not how but who?
The authors argue that payers and their agents can no longer remain passive when it comes to pricing combination therapies. Instead, they must actively own the value attribution process.
Towse A, Briggs A, Steuten L. Pricing combination products: not how but who? Eur J Health Econ. 2025 Apr 17. doi: 10.1007/s10198-025-01773-8.
Sleep Well, Spend Wisely
Cost-effectiveness analysis of Daridorexant for chronic insomnia
Discover whether investing in Daridorexant can deliver effective insomnia relief without breaking the healthcare budget - and review novel approaches to HTA submissions
Briggs AH, Chalet FX, Cooper J, Graham P, Palmer S, Miller P, Walker A, Greenwood B, Morin CM. Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults. Pharmacoecon Open. 2025 Mar 28
Fair Pricing for Combination Therapies
A solution to the 'not cost-effective at zero price' conundrum
Understand how equitable value attribution can resolve pricing disputes for combination treatments and improve patient access.
Briggs AH, Doyle-Connolly A, Schneider J, Podkonjak T, Taylor H, Roffe E, Low E, Davis S, Kaiser M, Hatswell AJ, Rabin N. An Attribution of Value Framework for Combination Treatments. Value Health. 2025 Jan;28(1):72-80.
Making Uncertainty Transparent
Reporting Uncertainty Around Health-State Values
Learn about standardized approaches to transparently managing and reporting uncertainty in health-state valuations.
Devlin NJ, Abangma G, Lloyd A, Parkin D, Briggs A. Reporting Uncertainty Around Health-State Values: A Standard Method and Worked Example. Value Health. 2025 Feb;28(2):191-196.
2024
When to Stop? Expert Views on aHUS Treatment Discontinuation
Treatment discontinuation in atypical hemolytic uremic syndrome
Gain insights into international experts' opinions on safely discontinuing expensive treatments, paired with a practical cost analysis.
Germeni E, Cooper J, Briggs A, Laurence J. Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts' perspectives with associated cost-consequence analysis. BMC Nephrol. 2024 Nov 14;25(1):411.
Patient Preference Data in HTA: Essential or Optional?
HTA representatives' perspectives on patient preference data
Explore whether patient preference data truly impacts decision-making in health technology assessments.
Germeni E, Fifer S, Hiligsmann M, Stein B, Tonkinson M, Joshi M, Hanna A, Liden B, Marshall DA. A genuine need or nice to have? Understanding HTA representatives' perspectives on the use of patient preference data. Int J Technol Assess Health Care. 2024 Nov 20;40(1):e60.
2023
Qualitative Research: The Missing Piece in HTA?
Beyond clinical and cost-effectiveness
Find out how qualitative research can significantly enrich health technology assessments beyond traditional quantitative methods.
Germeni E, Szabo S. Beyond clinical and cost-effectiveness: The contribution of qualitative research to health technology assessment. Int J Technol Assess Health Care. 2023 Apr 24;39(1):e23.
Translating Insomnia Severity into Health Values
Mapping Insomnia Severity Index to EQ-5D
Learn how the severity of insomnia symptoms can be effectively translated into actionable health-state utility values.
Chalet FX, Bujaroska T, Germeni E, Ghandri N, Maddalena ET, Modi K, Olopoenia A, Thompson J, Togninalli M, Briggs AH. Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective. Pharmacoecon Open. 2023 Jan;7(1):149-161.
A Critical Look at NICE’s Latest Methods Guidance
The evolving nature of Health Technology Assessment methods
Stay informed on the significant changes and implications of NICE’s updated guidelines for health technology assessment.
Angelis A, Harker M, Cairns J, Seo MK, Legood R, Miners A, Wiseman V, Chalkidou K, Grieve R, Briggs A. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual. Value Health. 2023 Oct;26(10):1503-1509.